Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Inflammatory Bowel Diseases

  Free Subscription


Articles published in Am J Gastroenterol

Retrieve available abstracts of 224 articles:
HTML format



Single Articles


    May 2022
  1. MARILD K, Soderling J, Lebwohl B, Green PH, et al
    ASSOCIATION OF CELIAC DISEASE AND INFLAMMATORY BOWEL DISEASE: A NATIONWIDE REGISTER-BASED COHORT STUDY.
    Am J Gastroenterol. 2022 May 25. pii: 00000434-990000000-00380.
    PubMed     Abstract available


    April 2022
  2. KAPLAN HC, Opipari-Arrigan L, Yang J, Schmid CH, et al
    Personalized Research on Diet in Ulcerative Colitis and Crohn's Disease (PRODUCE): A Series of N-of-1 Diet Trials.
    Am J Gastroenterol. 2022 Apr 20. pii: 00000434-990000000-00348.
    PubMed     Abstract available


  3. LUTZ M, Hayney MS, Caldera F
    We should not forget about patients with inflammatory bowel disease who received a COVID-19 viral vector vaccine.
    Am J Gastroenterol. 2022 Apr 15. pii: 00000434-990000000-00337.
    PubMed    


  4. DULAI PS, Rai V, Raffals LE, Lukin D, et al
    Recommendations on the appropriate management of steroids and discharge planning during and after hospital admission for moderate-severe ulcerative colitis: results of a RAND appropriateness panel.
    Am J Gastroenterol. 2022 Apr 13. pii: 00000434-990000000-00329.
    PubMed    


  5. SASSINE S, Djani L, Cambron-Asselin C, Savoie M, et al
    Risk Factors of Clinical Relapses in Pediatric Luminal Crohn's Disease: A Retrospective Cohort Study.
    Am J Gastroenterol. 2022;117:637-646.
    PubMed     Abstract available


    March 2022
  6. ROLAK S, Caldera F
    The current knowns and unknowns of COVID-19 vaccine induced immunity in patients with inflammatory bowel disease.
    Am J Gastroenterol. 2022 Mar 15. pii: 00000434-990000000-00282.
    PubMed    


  7. WINTER RW, Friedman S, Nielsen J, Kjeldsen J, et al
    Infliximab Is Not Associated With a General Long-Term Weight Gain in Patients With Inflammatory Bowel Disease: A Nationwide Study.
    Am J Gastroenterol. 2022 Mar 14. pii: 00000434-990000000-00278.
    PubMed     Abstract available


  8. KAPPELMAN MD, Weaver KN, Zhang X, Dai X, et al
    Factors Affecting Initial Humoral Immune Response to SARS-CoV-2 Vaccines Among Patients With Inflammatory Bowel Diseases.
    Am J Gastroenterol. 2022;117:462-469.
    PubMed     Abstract available


    February 2022
  9. SNINSKY JA, Barnes EL, Zhang X, Long MD, et al
    Urgency and its association with quality of life and clinical outcomes in ulcerative colitis patients.
    Am J Gastroenterol. 2022 Feb 15. pii: 00000434-990000000-00253.
    PubMed     Abstract available


    January 2022
  10. TSIPOTIS E, Frey S, Connolly C, Werbel WA, et al
    Antibody Response Three Months after Two-Dose SARS-CoV-2 mRNA Vaccination in patients with Inflammatory Bowel Disease.
    Am J Gastroenterol. 2022 Jan 29. pii: 00000434-990000000-00231.
    PubMed     Abstract available


  11. HAMADA K, Mankawa N, Yamamoto S
    May-Thurner syndrome in a patient with ulcerative colitis complicated by coronavirus disease 2019.
    Am J Gastroenterol. 2022 Jan 29. pii: 00000434-990000000-00233.
    PubMed    


  12. GARRIDO I, Lopes S, Andrade P, Real AC, et al
    Immune Response Induced by SARS-CoV-2 Vaccines in Patients With Inflammatory Bowel Disease Under Biologic Therapy.
    Am J Gastroenterol. 2022 Jan 24. pii: 00000434-990000000-00217.
    PubMed    


    December 2021
  13. MOLLY S, Margaret M, Erin F
    P076 The Role of Dual Biologic Therapy in Inflammatory Bowel Disease.
    Am J Gastroenterol. 2021;116.
    PubMed    


  14. JARED S, Edward B, Xian Z, Millie L, et al
    P075 Urgency and its Association with Quality of Life and Clinical Outcomes in Ulcerative Colitis Patients.
    Am J Gastroenterol. 2021;116.
    PubMed    


  15. RAHUL D, Jennifer M, Hannah G, Jessica A, et al
    P074 Comparative Risk of Clostridioides Difficile Infection in Vedolizumab vs anti-TNFa Agents in Biologic-Naive Patients With Ulcerative Colitis.
    Am J Gastroenterol. 2021;116.
    PubMed    


  16. BENJAMIN S, Kristine P, Kevin T, James M, et al
    P072 Non-invasive Vagal Nerve Stimulation to Treat Crohn Disease and Ulcerative Colitis in Children and Young Adults: A Proof-of-Concept Clinical Trial.
    Am J Gastroenterol. 2021;116.
    PubMed    


  17. JOSE RL, Jesus LG, Tomas CE, Korely TF, et al
    P063 Prevalence in the Use of Complementary/Alternative Medicine in Patients With Inflammatory Bowel Disease from Centro Medico Nacional 20 de Noviembre.
    Am J Gastroenterol. 2021;116.
    PubMed    


  18. KORELY TF, Jesus LG, Tomas CE, Rebeca PC, et al
    P061 Impact of Inflammatory Bowel Disease on sleep quality in a Mexican population attended in a referral center.
    Am J Gastroenterol. 2021;116.
    PubMed    


  19. VIVIANA PI, Jaiber G, Cristian F, Diego J, et al
    P060 Screening Criteria of Inflammatory Bowel Disease: Application in Colombian Patients With Spondyloarthritis.
    Am J Gastroenterol. 2021;116.
    PubMed    


  20. JULTON TC, Lauren S, Mouhammed S, Adil M, et al
    P058 Impact of Inflammatory Bowel Disease Treatment and Risk of Covid-19 Infection after Full Immunization: A Nationwide Analysis.
    Am J Gastroenterol. 2021;116.
    PubMed    


  21. CARLOS PA, Tomas CE, Jesus LG, Korely TF, et al
    P057 How Distance Between Residence and Treatment Center Impact the Outcome of Patients With Inflammatory Bowel Disease at CMN 20.
    Am J Gastroenterol. 2021;116.
    PubMed    


  22. VIVIANA PI, Juan FO, Pablo G, Consuelo RS, et al
    P056 Real life experience with the use of tofacitinib in ulcerative colitis in Colombia: case series.
    Am J Gastroenterol. 2021;116.
    PubMed    


  23. SANG TC, Sarah A, Yousef E, Joshua T, et al
    P055 Sociodemographic Differences in Fecal Enteropathogen Testing Patterns in Adults Hospitalized for Inflammatory Bowel Disease Flares.
    Am J Gastroenterol. 2021;116.
    PubMed    


  24. MIKAELL F, Ligia S, Adriana A, Roberto KJ, et al
    P052 National Registration of Patients With Inflammatory Bowel Disease in Brazil on Behalf of GEDIIB.
    Am J Gastroenterol. 2021;116.
    PubMed    


  25. MARTA F, Tiago LC, Vitor MS, Catia A, et al
    P051 Identifying High-Risk Patients With Acute Severe Ulcerative Colitis: Is the ACE Index Useful?
    Am J Gastroenterol. 2021;116.
    PubMed    


  26. VIVIANA PI, Katherin C, Julio A, Maria B, et al
    P050 Oral Inflammatory Changes Associated With Inflammatory Bowel Disease in Spondyloarthritis Associated With Early Endoscopic Findings.
    Am J Gastroenterol. 2021;116.
    PubMed    


  27. DANIEL S, Marina L, Ana Carolina O, Rodrigo B, et al
    P049 Investigation of Liver Diseases by Ultrasound in Patients With Inflammatory Bowel Disease.
    Am J Gastroenterol. 2021;116.
    PubMed    


  28. MARINA L, Daniel S, Ana Carolina O, Rodrigo B, et al
    P045 Prevalence of non-alcoholic fatty liver disease (NAFLD) in patients with inflammatory bowel disease (IBD) in a Brazilian public healthcare clinic.
    Am J Gastroenterol. 2021;116.
    PubMed    


  29. QIAN C, Myrlene S, Nurgul B, Lilla DS, et al
    P043 Resource Utilization and Productivity Loss among Patients with Inflammatory Bowel Disease in Sweden: A Longitudinal Nationwide Population-based Study.
    Am J Gastroenterol. 2021;116.
    PubMed    


  30. MILLIE L, Raymond C, Jonathan C, Marc P, et al
    P038 Ozanimod First-Dose Cardiac Effects in Patients with Moderately to Severely Active Ulcerative Colitis and Relapsing Multiple Sclerosis.
    Am J Gastroenterol. 2021;116.
    PubMed    


  31. JEAN-FREDERIC C, Geert D, Peter I, AnnKatrin P, et al
    P037 Effect of Ozanimod Treatment and Discontinuation on Absolute Lymphocyte Count in Moderate-to-Severe Ulcerative Colitis: Results from a Phase 3 Trial.
    Am J Gastroenterol. 2021;116.
    PubMed    


  32. DAVID H, Millie L, Douglas W, Stephen H, et al
    P035 Ozanimod for Moderate-to-Severe Ulcerative Colitis: North American Population Results During Induction and Maintenance in the Phase 3 True North Study.
    Am J Gastroenterol. 2021;116.
    PubMed    


  33. BRUCE S, Marc P, Michael S, AnnKatrin P, et al
    P031 Impact of Prior Biologic Exposure on Response to Ozanimod for Moderate-to-Severe Ulcerative Colitis in the Phase 3 True North Study.
    Am J Gastroenterol. 2021;116.
    PubMed    


  34. DAVID R, Remo P, Alison PB, Cem K, et al
    P028 Communicating Needs and Features of IBD Experiences (CONFIDE) Survey: Patient and Healthcare Professional Perspectives on Experience of Ulcerative Colitis Symptoms.
    Am J Gastroenterol. 2021;116.
    PubMed    


  35. APAAR D, Khushboo G, Jayesh R, Shesh R, et al
    P027 Brain Fog in Patients With Inflammatory Bowel Disease, and Association With Use of Probiotics.
    Am J Gastroenterol. 2021;116.
    PubMed    


  36. ADAM S, Nicole L, Heba I, Harini N, et al
    P026 Inflammatory Bowel Disease (IBD) Related Outcomes in Patients Diagnosed With COVID-19.
    Am J Gastroenterol. 2021;116.
    PubMed    


  37. SIGRID Y, Scott S, Shannon C
    P024 Anorectal Manometry in Patients with Fecal Incontinence After Ileal Pouch-Anal Anastomosis for Inflammatory Bowel Disease: A Cohort Study.
    Am J Gastroenterol. 2021;116.
    PubMed    


  38. KEVIN C, Sandra K, Noll R
    P023 Parental Distress in Pediatric Inflammatory Bowel Disease.
    Am J Gastroenterol. 2021;116.
    PubMed    


  39. VARUN J, Brian B, Esteban F
    P022 Biologic Therapy and Therapeutic Drug Monitoring in Patients With Inflammatory Bowel Disease and Primary Sclerosing Cholangitis.
    Am J Gastroenterol. 2021;116.
    PubMed    


  40. VITOR MS, Tiago LC, Marta F, Tiago CG, et al
    P020 Proton Pump Inhibitor Therapy: Providing "Acid" Outcomes in Patients With Inflammatory Bowel Disease Under Infliximab Treatment.
    Am J Gastroenterol. 2021;116.
    PubMed    


  41. IANA G, Randall J, Marc P
    P019 Not All Fecal Calprotectin is Specific for Inflammatory Bowel Disease.
    Am J Gastroenterol. 2021;116.
    PubMed    


  42. MARIYA Z, Oleg K, Karina N
    P017 Increased Level of Immunoglobulin G in the Development of Adverse Reactions in Patients With Ulcerative Colitis.
    Am J Gastroenterol. 2021;116.
    PubMed    


  43. RICHARD WY
    P011 Prevalence of Cannabis Use Disorder in Inflammatory Bowel Disease Hospitalizations in the United States and Effect on Length of Stay.
    Am J Gastroenterol. 2021;116.
    PubMed    


  44. HARTMAN B, Diana H, Casey C
    P009 Assessing the Status Quo: Ulcerative Colitis Monitoring in a Community GI Practice.
    Am J Gastroenterol. 2021;116.
    PubMed    


  45. OLEG K, Sergey K, Anna K, Albina L, et al
    P006 The Relationship of Histological Remission With the Duration of the Anamnesis Ulcerative Colitis.
    Am J Gastroenterol. 2021;116.
    PubMed    


  46. OLEG K, Anna K, Albina L, Anait B, et al
    P004 Steroid-Free Remission in Patients With Ulcerative Colitis Receiving Tofacitinib in Real Clinical Practice.
    Am J Gastroenterol. 2021;116.
    PubMed    


  47. HUI C, Tian F, Lintao D, Xuejie C, et al
    P003 Meat Consumption and All-Cause Mortality in 5763 Inflammatory Bowel Disease Patients: A Prospective Cohort Study.
    Am J Gastroenterol. 2021;116.
    PubMed    


  48. STONE M, Morrison M, Forster E
    P076 The Role of Dual Biologic Therapy in Inflammatory Bowel Disease.
    Am J Gastroenterol. 2021;116.
    PubMed     Abstract available


  49. SNINSKY J, Barnes E, Zhang X, Long M, et al
    P075 Urgency and its Association with Quality of Life and Clinical Outcomes in Ulcerative Colitis Patients.
    Am J Gastroenterol. 2021;116.
    PubMed     Abstract available


  50. DALAL R, Mitri J, Goodrick H, Allegretti J, et al
    P074 Comparative Risk of Clostridioides Difficile Infection in Vedolizumab vs anti-TNFa Agents in Biologic-Naive Patients With Ulcerative Colitis.
    Am J Gastroenterol. 2021;116.
    PubMed     Abstract available


  51. SAHN B, Pascuma K, Tracey K, Markowitz J, et al
    P072 Non-invasive Vagal Nerve Stimulation to Treat Crohn Disease and Ulcerative Colitis in Children and Young Adults: A Proof-of-Concept Clinical Trial.
    Am J Gastroenterol. 2021;116.
    PubMed     Abstract available


  52. ROMERO LJ, Gomez JL, Espinosa TC, Trujillo de la Fuente K, et al
    P063 Prevalence in the Use of Complementary/Alternative Medicine in Patients With Inflammatory Bowel Disease from Centro Medico Nacional 20 de Noviembre.
    Am J Gastroenterol. 2021;116.
    PubMed     Abstract available


  53. TRUJILLO DE LA FUENTE K, Lopez Gomez J, Cortes Espinosa T, Perez-Cabeza de Vaca R, et al
    P061 Impact of Inflammatory Bowel Disease on sleep quality in a Mexican population attended in a referral center.
    Am J Gastroenterol. 2021;116.
    PubMed     Abstract available


  54. PARRA IZQUIERDO V, Gutierrez J, Florez C, Jaimes D, et al
    P060 Screening Criteria of Inflammatory Bowel Disease: Application in Colombian Patients With Spondyloarthritis.
    Am J Gastroenterol. 2021;116.
    PubMed     Abstract available


  55. PAREDES AMENABAR C, Cortes Espinosa T, Lopez Gomez J, Trujillo de la Fuente K, et al
    P057 How Distance Between Residence and Treatment Center Impact the Outcome of Patients With Inflammatory Bowel Disease at CMN 20.
    Am J Gastroenterol. 2021;116.
    PubMed     Abstract available


  56. PARRA IZQUIERDO V, Frias-Ordonez J, Galindo P, Romero-Sanchez C, et al
    P056 Real life experience with the use of tofacitinib in ulcerative colitis in Colombia: case series.
    Am J Gastroenterol. 2021;116.
    PubMed     Abstract available


  57. TSE CS, Andrea S, Elfanagely Y, Tanzer J, et al
    P055 Sociodemographic Differences in Fecal Enteropathogen Testing Patterns in Adults Hospitalized for Inflammatory Bowel Disease Flares.
    Am J Gastroenterol. 2021;116.
    PubMed     Abstract available


  58. FARIA M, Sassaki L, Andrade A, Kaiser Junior R, et al
    P052 National Registration of Patients With Inflammatory Bowel Disease in Brazil on Behalf of GEDIIB.
    Am J Gastroenterol. 2021;116.
    PubMed     Abstract available


  59. FREITAS M, Capela TL, Macedo Silva V, Arieira C, et al
    P051 Identifying High-Risk Patients With Acute Severe Ulcerative Colitis: Is the ACE Index Useful?
    Am J Gastroenterol. 2021;116.
    PubMed     Abstract available


  60. PARRA IZQUIERDO V, Chumacero K, Alvarado J, Buenahora M, et al
    P050 Oral Inflammatory Changes Associated With Inflammatory Bowel Disease in Spondyloarthritis Associated With Early Endoscopic Findings.
    Am J Gastroenterol. 2021;116.
    PubMed     Abstract available


  61. SHINTAKU D, Lopes M, de Oliveira AC, Beraldo R, et al
    P049 Investigation of Liver Diseases by Ultrasound in Patients With Inflammatory Bowel Disease.
    Am J Gastroenterol. 2021;116.
    PubMed     Abstract available


  62. LOPES M, Shintaku D, de Oliveira AC, Beraldo R, et al
    P045 Prevalence of non-alcoholic fatty liver disease (NAFLD) in patients with inflammatory bowel disease (IBD) in a Brazilian public healthcare clinic.
    Am J Gastroenterol. 2021;116.
    PubMed     Abstract available


  63. CAI Q, Sanon M, Batyrbekova N, Di Scala L, et al
    P043 Resource Utilization and Productivity Loss among Patients with Inflammatory Bowel Disease in Sweden: A Longitudinal Nationwide Population-based Study.
    Am J Gastroenterol. 2021;116.
    PubMed     Abstract available


  64. LONG M, Cross R, Calkwood J, Pondel M, et al
    P038 Ozanimod First-Dose Cardiac Effects in Patients with Moderately to Severely Active Ulcerative Colitis and Relapsing Multiple Sclerosis.
    Am J Gastroenterol. 2021;116.
    PubMed     Abstract available


  65. COLOMBEL JF, D'Haens G, Irving P, Petersen A, et al
    P037 Effect of Ozanimod Treatment and Discontinuation on Absolute Lymphocyte Count in Moderate-to-Severe Ulcerative Colitis: Results from a Phase 3 Trial.
    Am J Gastroenterol. 2021;116.
    PubMed     Abstract available


  66. HUDESMAN D, Long M, Wolf D, Hanauer S, et al
    P035 Ozanimod for Moderate-to-Severe Ulcerative Colitis: North American Population Results During Induction and Maintenance in the Phase 3 True North Study.
    Am J Gastroenterol. 2021;116.
    PubMed     Abstract available


  67. SANDS B, Pondel M, Silver M, Petersen A, et al
    P031 Impact of Prior Biologic Exposure on Response to Ozanimod for Moderate-to-Severe Ulcerative Colitis in the Phase 3 True North Study.
    Am J Gastroenterol. 2021;116.
    PubMed     Abstract available


  68. RUBIN D, Panaccione R, Potts Bleakman A, Kayhan C, et al
    P028 Communicating Needs and Features of IBD Experiences (CONFIDE) Survey: Patient and Healthcare Professional Perspectives on Experience of Ulcerative Colitis Symptoms.
    Am J Gastroenterol. 2021;116.
    PubMed     Abstract available


  69. DADLANI A, Gala K, Rai J, Rai S, et al
    P027 Brain Fog in Patients With Inflammatory Bowel Disease, and Association With Use of Probiotics.
    Am J Gastroenterol. 2021;116.
    PubMed     Abstract available


  70. YOUNG S, Smukalla S, Chang S
    P024 Anorectal Manometry in Patients with Fecal Incontinence After Ileal Pouch-Anal Anastomosis for Inflammatory Bowel Disease: A Cohort Study.
    Am J Gastroenterol. 2021;116.
    PubMed     Abstract available


  71. CESA K, Kim S, Robert N
    P023 Parental Distress in Pediatric Inflammatory Bowel Disease.
    Am J Gastroenterol. 2021;116.
    PubMed     Abstract available


  72. JAIN V, Behm B, Figueroa E
    P022 Biologic Therapy and Therapeutic Drug Monitoring in Patients With Inflammatory Bowel Disease and Primary Sclerosing Cholangitis.
    Am J Gastroenterol. 2021;116.
    PubMed     Abstract available


  73. MACEDO SILVA V, Lima Capela T, Freitas M, Curdia Goncalves T, et al
    P020 Proton Pump Inhibitor Therapy: Providing "Acid" Outcomes in Patients With Inflammatory Bowel Disease Under Infliximab Treatment.
    Am J Gastroenterol. 2021;116.
    PubMed     Abstract available


  74. GUEORGUIEVA I, Jacobs R, Piper M
    P019 Not All Fecal Calprotectin is Specific for Inflammatory Bowel Disease.
    Am J Gastroenterol. 2021;116.
    PubMed     Abstract available


  75. ZVYAGLOVA M, Knyazev O, Noscova K
    P017 Increased Level of Immunoglobulin G in the Development of Adverse Reactions in Patients With Ulcerative Colitis.
    Am J Gastroenterol. 2021;116.
    PubMed     Abstract available


  76. WANG YR
    P011 Prevalence of Cannabis Use Disorder in Inflammatory Bowel Disease Hospitalizations in the United States and Effect on Length of Stay.
    Am J Gastroenterol. 2021;116.
    PubMed     Abstract available


  77. BRUNT H, Hamer D, Chapman C
    P009 Assessing the Status Quo: Ulcerative Colitis Monitoring in a Community GI Practice.
    Am J Gastroenterol. 2021;116.
    PubMed     Abstract available


  78. KNYAZEV O, Khomeriki S, Kagramanova A, Lishchinskaya A, et al
    P006 The Relationship of Histological Remission With the Duration of the Anamnesis Ulcerative Colitis.
    Am J Gastroenterol. 2021;116.
    PubMed     Abstract available


  79. KNYAZEV O, Kagramanova A, Lishchinskaya A, Babayan A, et al
    P004 Steroid-Free Remission in Patients With Ulcerative Colitis Receiving Tofacitinib in Real Clinical Practice.
    Am J Gastroenterol. 2021;116.
    PubMed     Abstract available


  80. CHEN H, Fu T, Dan L, Chen X, et al
    P003 Meat Consumption and All-Cause Mortality in 5763 Inflammatory Bowel Disease Patients: A Prospective Cohort Study.
    Am J Gastroenterol. 2021;116.
    PubMed     Abstract available


  81. DAI C, Jiang M, Huang YH
    The Association Between Serum Infliximab Concentrations and Clinical Outcomes in Fistulizing Crohn's Disease.
    Am J Gastroenterol. 2021;116:2481-2482.
    PubMed    


    November 2021
  82. MELMED GY, Oliver B, Hou JK, Lum D, et al
    Quality of Care Program Reduces Unplanned Health Care Utilization in Patients With Inflammatory Bowel Disease.
    Am J Gastroenterol. 2021 Nov 19. pii: 00000434-990000000-00153.
    PubMed     Abstract available


  83. CALDERA F, Knutson KL, Saha S, Wald A, et al
    Humoral Immunogenicity of mRNA COVID-19 Vaccines Among Patients With Inflammatory Bowel Disease and Healthy Controls.
    Am J Gastroenterol. 2021 Nov 18. pii: 00000434-990000000-00148.
    PubMed     Abstract available


  84. BRUNT H, Chapman JC
    The Inflammatory Bowel Disease-Focused Primary Care Provider: An Addition to the IBD Specialty Medical Home.
    Am J Gastroenterol. 2021 Nov 17. pii: 00000434-990000000-00144.
    PubMed    


  85. NGUYEN NH, Martinez I, Atreja A, Sitapati AM, et al
    Digital Health Technologies for Remote Monitoring and Management of Inflammatory Bowel Disease: A Systematic Review.
    Am J Gastroenterol. 2021 Nov 9. pii: 00000434-990000000-00141.
    PubMed     Abstract available


  86. ALMARIO CV, Kogan L, van Deen WK, Scott FI, et al
    Health Economic Impact of a Multicenter Quality-of-Care Initiative for Reducing Unplanned Healthcare Utilization Among Patients With Inflammatory Bowel Disease.
    Am J Gastroenterol. 2021 Nov 3. pii: 00000434-990000000-00133.
    PubMed     Abstract available


  87. CHO JM, Loftus EV Jr, Bruining DH, Chedid VG, et al
    Vulvar Crohn's Disease: Clinical Features and Outcomes.
    Am J Gastroenterol. 2021;116:2296-2299.
    PubMed     Abstract available


    October 2021
  88. LAUBE R, Tran Y, Paramsothy S, Leong RW, et al
    Assisted Reproductive Technology in Crohn's Disease and Ulcerative Colitis: A Systematic Review and Meta-Analysis.
    Am J Gastroenterol. 2021 Oct 25. pii: 00000434-990000000-00131.
    PubMed     Abstract available


  89. THAKUR K, Barrett TA
    Social Determinants of Health in Inflammatory Bowel Diseases: Barriers and Opportunities.
    Am J Gastroenterol. 2021;116:2146.
    PubMed    


  90. ASHHAB AA, Lee M, Melmed GY
    Extensive Upper Gastrointestinal Fistulization in Crohn's Disease, an Uncommon Cause for a Common Presentation.
    Am J Gastroenterol. 2021;116:1978.
    PubMed    


    September 2021
  91. BATTAT R, Long MD
    Is Proactive Therapeutic Drug Monitoring Ready for the Spotlight in Inflammatory Bowel Disease? Follow the Data.
    Am J Gastroenterol. 2021 Sep 13. pii: 00000434-990000000-00100.
    PubMed     Abstract available


    August 2021
  92. SANGHA M, Roitman I, Sultan K, Swaminath A, et al
    SARS-CoV-2 Immunization in Patients With Inflammatory Bowel Disease May Result in Disease Flares.
    Am J Gastroenterol. 2021 Aug 18. pii: 00000434-990000000-00081.
    PubMed    


  93. CHEIFETZ AS, Abreu MT, Afif W, Cross RK, et al
    A Comprehensive Literature Review and Expert Consensus Statement on Therapeutic Drug Monitoring of Biologics in Inflammatory Bowel Disease.
    Am J Gastroenterol. 2021 Aug 13. pii: 00000434-990000000-00067.
    PubMed     Abstract available


  94. RICCIUTO A, Carman N, Benchimol EI, Siddiqui I, et al
    Prospective Evaluation of Endoscopic and Histologic Indices in Pediatric Ulcerative Colitis Using Centralized Review.
    Am J Gastroenterol. 2021 Aug 13. pii: 00000434-990000000-00066.
    PubMed     Abstract available


  95. DULAI PS, Jairath V, Narula N, Wong E, et al
    A Microsimulation Model to Determine the Cost-Effectiveness of Treat-to-Target Strategies for Crohn's Disease.
    Am J Gastroenterol. 2021;116:1709-1719.
    PubMed     Abstract available


    July 2021
  96. HARRISON N, Humes R, Singla M
    Skip, Stop, Switch, and Spare: Steroid Therapy in Inflammatory Bowel Disease.
    Am J Gastroenterol. 2021 Jul 19. pii: 00000434-990000000-00049.
    PubMed    


  97. SCHUMANN M, Sonnenberg E, Siegmund B, Meier K, et al
    A 39-Year-Old Man With Crohn's Disease and a Unclear Rash on His Left Cheek.
    Am J Gastroenterol. 2021;116:1374.
    PubMed    


    June 2021
  98. ABDALLA MI, Levesque BG
    Progress in Corticosteroid Use in the Era of Biologics With Room for Improvement.
    Am J Gastroenterol. 2021;116:1187-1188.
    PubMed     Abstract available


  99. TARGOWNIK LE, Bernstein CN, Benchimol EI, Kaplan GG, et al
    Trends in Corticosteroid Use During the Era of Biologic Therapy: A Population-Based Analysis.
    Am J Gastroenterol. 2021;116:1284-1293.
    PubMed     Abstract available


    May 2021
  100. DE GIORGI V, Trane L, Silvestri F, Venturi F, et al
    Pyodermatitis-Pyostomatitis Vegetans in Active Inflammatory Bowel Disease.
    Am J Gastroenterol. 2021 May 31. pii: 00000434-900000000-98762.
    PubMed    


  101. BOTWIN GJ, Li D, Figueiredo J, Cheng S, et al
    Adverse Events Following SARS-CoV-2 mRNA Vaccination: Among Patients with Inflammatory Bowel Disease.
    Am J Gastroenterol. 2021 May 25. pii: 00000434-900000000-98766.
    PubMed     Abstract available


  102. TEICH N, Stallmach A, Bruns T
    Greenspace in Childhood: A New Avenue to Prevent Inflammatory Bowel Disease?
    Am J Gastroenterol. 2021 May 7. pii: 00000434-900000000-98784.
    PubMed    


  103. TANG J, Huang Z, Guo H, Ding N, et al
    Online Video Clinic Satisfies the Medical Requirements of Patients with IBD During the COVID-19 Outbreak.
    Am J Gastroenterol. 2021;116:1087.
    PubMed    


  104. PAPAMICHAEL K, Vande Casteele N, Jeyarajah J, Jairath V, et al
    Higher Postinduction Infliximab Concentrations Are Associated With Improved Clinical Outcomes in Fistulizing Crohn's Disease: An ACCENT-II Post Hoc Analysis.
    Am J Gastroenterol. 2021;116:1007-1014.
    PubMed     Abstract available


    April 2021
  105. KHAN N, Patel D, Xie D, Pernes T, et al
    Are Patients With Inflammatory Bowel Disease at an Increased Risk of Developing SARS-CoV-2 than Patients Without Inflammatory Bowel Disease? Results From a Nationwide Veterans' Affairs Cohort Study.
    Am J Gastroenterol. 2021;116:808-810.
    PubMed     Abstract available


  106. KHAN N, Patel D, Trivedi C, Kavani H, et al
    Incidence of Acute Myeloid Leukemia and Myelodysplastic Syndrome in Patients With Inflammatory Bowel Disease and the Impact of Thiopurines on Their Risk.
    Am J Gastroenterol. 2021;116:741-747.
    PubMed     Abstract available


  107. SONNENBERG A
    Do Forgotten Symptoms Need Treatment?
    Am J Gastroenterol. 2021;116:841-842.
    PubMed    


  108. HA C
    The Age-Old Conundrum With Thiopurines: Are the Accumulating Risks Greater Than Benefits?
    Am J Gastroenterol. 2021;116:671-672.
    PubMed     Abstract available


    March 2021
  109. BERNSTEIN CN, Nugent Z, Singh H
    Persistently High Rate of Venous Thromboembolic Disease in Inflammatory Bowel Disease: A Population-Based Study.
    Am J Gastroenterol. 2021 Mar 24. pii: 00000434-900000000-98845.
    PubMed     Abstract available


  110. SLATER NR, Loomes DE
    Endoscopic Vacuum-Assisted Wound Closure of a Rectal Perforation in the Setting of Active Ulcerative Colitis.
    Am J Gastroenterol. 2021 Mar 2. pii: 00000434-900000000-98819.
    PubMed    


    January 2021
  111. COELHO-PRABHU N, Kane S
    Does Size Really Matter?
    Am J Gastroenterol. 2021;116:84-85.
    PubMed     Abstract available


  112. HAMMOUDI N, Allez M
    Response to Hanzel.
    Am J Gastroenterol. 2021;116:218.
    PubMed    


  113. HANZEL J
    A Novel Endoscopic Score for Postoperative Recurrence of Crohn's Disease: More Information Needed.
    Am J Gastroenterol. 2021;116:217-218.
    PubMed    


  114. RIVIERE P, D'Haens G, Peyrin-Biroulet L, Baert F, et al
    Location but Not Severity of Endoscopic Lesions Influences Endoscopic Remission Rates in Crohn's Disease: A Post Hoc Analysis of TAILORIX.
    Am J Gastroenterol. 2021;116:134-141.
    PubMed     Abstract available


    December 2020
  115. LACY BE, Pimentel M, Brenner DM, Chey WD, et al
    ACG Clinical Guideline: Management of Irritable Bowel Syndrome.
    Am J Gastroenterol. 2020 Dec 14. doi: 10.14309/ajg.0000000000001036.
    PubMed     Abstract available


  116. KORELITZ BI, Sachar DB, Schneider J
    Full Potential of 6-Mercaptopurine in IBD May Remain Untapped.
    Am J Gastroenterol. 2020;115:2109-2110.
    PubMed    


  117. FERNANDA F, Mirella O, Danielle F, Pedro G, et al
    P074 Prevalence and Associated Factors With Non-Adherence to Maintenance Therapy for Ulcerative Colitis in Deep Remission.
    Am J Gastroenterol. 2020;115.
    PubMed    


  118. PRADEEP KR, Deloshaan S, Dheeraj S, Hadi M, et al
    P070 Outcomes of Acute Severe Ulcerative Colitis in Older Adults.
    Am J Gastroenterol. 2020;115.
    PubMed    


  119. DELOSHAAN S, Pradeep KR, Dheeraj S, Hadi M, et al
    P069 Admission Steroid Use, Serum Albumin and Endoscopic Severity Predict Intravenous Steroid Failure in Patients With Acute Severe Ulcerative Colitis.
    Am J Gastroenterol. 2020;115.
    PubMed    


  120. JAQUELINE B, Juliana C, Dos Santos B, Caroline D, et al
    P068 Therapeutic Aspects in Pediatric Inflammatory Bowel Disease - A Multi-Centric Study From Brazil.
    Am J Gastroenterol. 2020;115.
    PubMed    


  121. FLAVIA P, Cyrla Z, de Souza H, Jessica M, et al
    P066 Hospitalization and Surgery Rates in Patients With Inflammatory Bowel Disease in Brazil: A Time-Trend Analysis.
    Am J Gastroenterol. 2020;115.
    PubMed    


  122. JENNIFER MO, Megan L, Jean A
    P065 Inflammatory Bowel Disease or Bowel Endometriosis? Two Cases of Large Bowel Obstruction.
    Am J Gastroenterol. 2020;115.
    PubMed    


  123. JAQUELINE B, Juliana C, Dos Santos Beatriz, Caroline D, et al
    P064 Clinical Aspects of Pediatric Inflammatory Bowel Disease - A Multicentric Study From Brazil.
    Am J Gastroenterol. 2020;115.
    PubMed    


  124. FABIANA B, Cesar A, Marcio C, Carolina M, et al
    P061 Prophylaxis of Hepatitis B Reactivation and Inflammatory Bowel Disease: A case report.
    Am J Gastroenterol. 2020;115.
    PubMed    


  125. SVETLANA L, Morris G, Vasiliki S
    P056 Power Calculations in Randomised Controlled Trials of Inflammatory Bowel Disease.
    Am J Gastroenterol. 2020;115.
    PubMed    


  126. WALAA M, Hisham W, Walid H, Fadi F, et al
    P049 Should the Gallbladder be Empirically Removed at Time of Intestinal Resection in Inflammatory Bowel Disease Patients?
    Am J Gastroenterol. 2020;115.
    PubMed    


  127. ERIC J
    P047 Awareness and Impact of Recent AGA Guideline Changes for Moderate to Severe Ulcerative Colitis Patients.
    Am J Gastroenterol. 2020;115.
    PubMed    


  128. ERIC J
    P046 Though Biosimilar Infliximab Prescribing in Inflammatory Bowel Disease Has Increased, Branded Infliximab Continues to Be Prescribed More Often.
    Am J Gastroenterol. 2020;115.
    PubMed    


  129. CASEY C, Jenny G, Michelle B, Joe L, et al
    P042 The CONCERT Initiative: Impact of Inflammatory Bowel Disease Care Referral Pathway.
    Am J Gastroenterol. 2020;115.
    PubMed    


  130. SARA L, Millie L, Uma M
    P040 Indications for Cesarean Section in Pregnant Women with Inflammatory Bowel Disease: Results from the PIANO Registry.
    Am J Gastroenterol. 2020;115.
    PubMed    


  131. SARA H, David H, Joe Z, Ryan H, et al
    P038 Factors Associated with Impaired Patient-Reported Outcomes and Work Productivity Among Patients with Ulcerative Colitis in Remission.
    Am J Gastroenterol. 2020;115.
    PubMed    


  132. DAVID P, Caterina O, Christopher A, Gregory AC, et al
    P037 Efficacy and Safety of 1-L NER1006 Bowel Preparation in Patients with Inflammatory Bowel Disease: Analysis of 2 Phase 3 Studies.
    Am J Gastroenterol. 2020;115.
    PubMed    


  133. CLARA U, Amanda T, Debora T, Giovana C, et al
    P036 Clinical and Psychological Factors Associated with Impaired Body Image in Patients with Inflammatory Bowel Disease.
    Am J Gastroenterol. 2020;115.
    PubMed    


  134. KAUSTAV S, Austin T, Roman G, Allison M, et al
    P033 Demographic Factors Associated with Successful Telehealth Visits in Inflammatory Bowel Disease Patients.
    Am J Gastroenterol. 2020;115.
    PubMed    


  135. WILLIAM S, Brian F, Stephen H, Severine V, et al
    P031 Ozanimod in Patients with Moderate-to-Severe Ulcerative Colitis: Long-Term Safety and Efficacy from the Phase 2 TOUCHSTONE Study 4-Year Open-Label Extension.
    Am J Gastroenterol. 2020;115.
    PubMed    


  136. SILVIO D, Brian F, Stephen H, Igor J, et al
    P030 Ozanimod Efficacy, Safety, and Histology in Patients with Moderate-to-Severe Ulcerative Colitis During Maintenance in the Phase 3 True North Study.
    Am J Gastroenterol. 2020;115.
    PubMed    


  137. EDWARD B, Harris A, Joe Z, Antoine S, et al
    P027 Factors Associated with Biologic Discontinuation in Patients with Inflammatory Bowel Disease in TARGET-IBD.
    Am J Gastroenterol. 2020;115.
    PubMed    


  138. SHINTARO A, Jacob O, Cindy T, Victoria R, et al
    P026 Assessment of Contributing Factors for Fistula Development in Patients with Inflammatory Bowel Disease Treated by Proctocolectomy with Ileal Pouch-Anal Anastomosis.
    Am J Gastroenterol. 2020;115.
    PubMed    


  139. WILLIAM S, Geert D, Doug W, Stephen H, et al
    P025 Ozanimod Efficacy, Safety, and Histology in Patients with Moderate-to-Severe Ulcerative Colitis During Induction in the Phase 3 True North Study.
    Am J Gastroenterol. 2020;115.
    PubMed    


  140. GALIYA B, Alisa R, Maria L
    P024 Medical Decision Support System in the Diagnosis of Ulcerative Colitis.
    Am J Gastroenterol. 2020;115.
    PubMed    


  141. MICHAEL C, Puza S, Benjamin C, Leonardo S, et al
    P021 Characteristics of Patients Treated with Tofacitinib for Ulcerative Colitis in the Real World: Findings from a Large US Claims Database.
    Am J Gastroenterol. 2020;115.
    PubMed    


  142. SUBRATA G, Geert D, Vipul J, Florian R, et al
    P012 Ozanimod Reduced Fecal Calprotectin Levels in Patients with Ulcerative Colitis in the Phase 3 True North Study.
    Am J Gastroenterol. 2020;115.
    PubMed    


  143. ROGERIO P, Julio C, Liliana C, Erika B, et al
    P008 Long-Term Effectiveness and Safety of Ustekinumab for The Treatment of Crohn s Disease: A Brazilian Multicentre Real-world Study.
    Am J Gastroenterol. 2020;115.
    PubMed    


  144. OLEG K, Albina L, Anatoliy K, Anna K, et al
    P005 Overcoming Secondary Loss of Response to Infliximab in Patients With Ulcerative Colitis With the Use of Mesenchymal Stromal Cells.
    Am J Gastroenterol. 2020;115.
    PubMed    


  145. OLEG K, Anna K, Albina L, Tatyana S, et al
    P002 Frequency and Causes of Prolongation of the Induction Course of Tofacitinib in Patients with Ulcerative Colitis.
    Am J Gastroenterol. 2020;115.
    PubMed    


  146. ERNESTO R, Rachel H, Meera L, Pablo P, et al
    P001 North-South Gradient in the Incidence of Pediatric Inflammatory Bowel Disease Along the Atlantic Coast.
    Am J Gastroenterol. 2020;115.
    PubMed    


    November 2020
  147. KHAN N, Patel D, Trivedi C, Kavani H, et al
    Incidence of Acute Myeloid Leukemia and Myelodysplastic Syndrome in Patients With Inflammatory Bowel Disease and the Impact of Thiopurines on Their Risk.
    Am J Gastroenterol. 2020 Nov 26. doi: 10.14309/ajg.0000000000001058.
    PubMed     Abstract available


  148. ZAVER HB, Ghoz H, Azar A, Alexander LF, et al
    Inferior Mesenteric Arteriovenous Malformation Masquerading as Ulcerative Colitis.
    Am J Gastroenterol. 2020 Nov 10. doi: 10.14309/ajg.0000000000000917.
    PubMed    


  149. CHAPARRO M, Gordillo J, Domenech E, Esteve M, et al
    Fendrix vs Engerix-B for Primo-Vaccination Against Hepatitis B Infection in Patients With Inflammatory Bowel Disease: A Randomized Clinical Trial.
    Am J Gastroenterol. 2020;115:1802-1811.
    PubMed     Abstract available


  150. BANTY A, Melmed GY
    Improving Hepatitis B Virus Vaccination Responses in Inflammatory Bowel Disease: Does Greater Dose and Greater Frequency Lead to Greater Protection?
    Am J Gastroenterol. 2020;115:1797-1798.
    PubMed     Abstract available


  151. LITTLE DHW, Tabatabavakili S, Shaffer SR, Nguyen GC, et al
    Effectiveness of Dose De-escalation of Biologic Therapy in Inflammatory Bowel Disease: A Systematic Review.
    Am J Gastroenterol. 2020;115:1768-1774.
    PubMed     Abstract available


  152. WINDSOR JW, Underwood FE, Brenner E, Colombel JF, et al
    Data Visualization in the Era of COVID-19: An Interactive Map of the SECURE-IBD Registry.
    Am J Gastroenterol. 2020;115:1923-1924.
    PubMed    


  153. CHAPUIS-BIRON C, Kirchgesner J, Pariente B, Bouhnik Y, et al
    Ustekinumab for Perianal Crohn's Disease: The BioLAP Multicenter Study From the GETAID.
    Am J Gastroenterol. 2020;115:1812-1820.
    PubMed     Abstract available


    October 2020
  154. BUCHNER AM, Schneider Y, Lichtenstein GR
    Biosimilars in Inflammatory Bowel Disease.
    Am J Gastroenterol. 2020 Oct 27. doi: 10.14309/ajg.0000000000000844.
    PubMed     Abstract available


  155. GUBATAN J, Nielsen OH, Levitte S, Juhl CB, et al
    Biologics During Pregnancy in Women With Inflammatory Bowel Disease and Risk of Infantile Infections: A Systematic Review and Meta-Analysis.
    Am J Gastroenterol. 2020 Oct 23. doi: 10.14309/ajg.0000000000000910.
    PubMed     Abstract available


  156. KHAN N, Patel D, Xie D, Pernes T, et al
    Are Patients With Inflammatory Bowel Disease at an Increased Risk of Developing SARS-CoV-2 than Patients Without Inflammatory Bowel Disease? Results From a Nationwide Veterans' Affairs Cohort Study.
    Am J Gastroenterol. 2020 Oct 19. doi: 10.14309/ajg.0000000000001012.
    PubMed     Abstract available


  157. ELTEN M, Benchimol EI, Fell DB, Kuenzig ME, et al
    Residential Greenspace in Childhood Reduces Risk of Pediatric Inflammatory Bowel Disease: A Population-Based Cohort Study.
    Am J Gastroenterol. 2020 Oct 8. doi: 10.14309/ajg.0000000000000990.
    PubMed     Abstract available


  158. FIORINO G, Gilardi D, Radice S, Furfaro F, et al
    Absence of COVID-19 Infection in Patients Accessing IBD Unit at Humanitas, Milan: Implications for Postlockdown Measures.
    Am J Gastroenterol. 2020;115:1719-1721.
    PubMed     Abstract available


  159. MANSOOR E, Khoudari G, Abou Saleh M, Elfadawy N, et al
    The Many Faces of COVID-19: Atypical Presentation of COVID-19 in a Patient With Crohn's Disease With Acute Diarrhea Leading to Severe Hypovolemic Hyponatremia-A Case Report.
    Am J Gastroenterol. 2020;115:1730-1731.
    PubMed    


  160. GIESE-KIM N, Wu M, Dehghan M, Sceats LA, et al
    Home Infliximab Infusions Are Associated With Suboptimal Outcomes Without Cost Savings in Inflammatory Bowel Diseases.
    Am J Gastroenterol. 2020;115:1698-1706.
    PubMed     Abstract available


    September 2020
  161. CHAPARRO M, Gordillo J, Domenech E, Esteve M, et al
    Fendrix vs Engerix-B for Primo-Vaccination Against Hepatitis B Infection in Patients With Inflammatory Bowel Disease: A Randomized Clinical Trial.
    Am J Gastroenterol. 2020 Sep 30. doi: 10.14309/ajg.0000000000000926.
    PubMed     Abstract available


  162. BANTY A, Melmed GY
    Improving Hepatitis B Virus Vaccination Responses in Inflammatory Bowel Disease: Does Greater Dose and Greater Frequency Lead to Greater Protection?
    Am J Gastroenterol. 2020 Sep 25. doi: 10.14309/ajg.0000000000000921.
    PubMed     Abstract available


  163. SHAFFER SR, Huang E, Patel S, Rubin DT, et al
    Cost-Effectiveness of 5-Aminosalicylate Therapy in Combination With Biologics or Tofacitinib in the Treatment of Ulcerative Colitis.
    Am J Gastroenterol. 2020 Sep 16. doi: 10.14309/ajg.0000000000000847.
    PubMed     Abstract available


  164. LONG MD
    Shining a Light on Skin Cancer in Inflammatory Bowel Disease: A Role for Prevention.
    Am J Gastroenterol. 2020 Sep 11. doi: 10.14309/ajg.0000000000000775.
    PubMed     Abstract available


  165. KAMAL N, Bookwalter A, Foss R, Cross RK, et al
    Pyostomatitis Vegetans: An Unusual Oral Manifestation of Inflammatory Bowel Disease.
    Am J Gastroenterol. 2020;115:1385.
    PubMed    


  166. DALAL RS, Palchaudhuri S, Snider CK, Gitelman Y, et al
    A Multimodal Intervention Using Nonopioid Analgesics Is Associated With Reduced Intravenous Opioid Exposure Among Hospitalized Patients With Inflammatory Bowel Diseases.
    Am J Gastroenterol. 2020;115:1474-1485.
    PubMed     Abstract available


  167. QUINN KP, Raffals LE
    An Update on the Medical Management of Inflammatory Pouch Complications.
    Am J Gastroenterol. 2020;115:1439-1450.
    PubMed     Abstract available


    August 2020
  168. LICHTENSTEIN GR, Rubin DT
    Coronavirus and Patients With Inflammatory Bowel Disease: Management Strategies for the Practicing Clinician.
    Am J Gastroenterol. 2020 Aug 24. doi: 10.14309/ajg.0000000000000817.
    PubMed    


  169. COHEN BL, Hanauer SB
    Executive Summary of 'Development of Entrustable Professional Activities for Advanced Inflammatory Bowel Disease Fellowship Training in the United States'.
    Am J Gastroenterol. 2020 Aug 20. doi: 10.14309/ajg.0000000000000809.
    PubMed    


  170. PAPA A, Gasbarrini A, Tursi A
    Epidemiology and the Impact of Therapies on the Outcome of COVID-19 in Patients With Inflammatory Bowel Disease.
    Am J Gastroenterol. 2020 Aug 19. doi: 10.14309/ajg.0000000000000830.
    PubMed     Abstract available


  171. RAPHAEL KL, Trindade AJ, Zimmerman HM, Sultan KS, et al
    Endoscopic Evaluation of Inflammatory Bowel Disease With High-Grade Dysplasia Should Not Be Delayed During the COVID-19 Pandemic: A Case Report.
    Am J Gastroenterol. 2020 Aug 19. doi: 10.14309/ajg.0000000000000813.
    PubMed    


  172. BERNSTEIN CN, Walld R, Marrie RA
    Social Determinants of Outcomes in Inflammatory Bowel Disease.
    Am J Gastroenterol. 2020 Aug 5. doi: 10.14309/ajg.0000000000000794.
    PubMed     Abstract available


  173. WOLF DC, Wolf CH, Rubin DT
    Temporal Improvement of a COVID-19-Positive Crohn's Disease Patient Treated With Bismuth Subsalicylate.
    Am J Gastroenterol. 2020;115:1298.
    PubMed    


  174. NARULA N, Wong ECL, Aruljothy A, Dulai PS, et al
    Ileal and Rectal Ulcer Size Affects the Ability to Achieve Endoscopic Remission: A Post hoc Analysis of the SONIC Trial.
    Am J Gastroenterol. 2020;115:1236-1245.
    PubMed     Abstract available


    July 2020
  175. LITTLE DHW, Tabatabavakili S, Shaffer SR, Nguyen GC, et al
    Effectiveness of Dose De-escalation of Biologic Therapy in Inflammatory Bowel Disease: A Systematic Review.
    Am J Gastroenterol. 2020 Jul 27. doi: 10.14309/ajg.0000000000000783.
    PubMed     Abstract available


  176. BHAT S, Farraye FA, Moss AC
    Impact of Clinical Pharmacists in Inflammatory Bowel Disease Centers During the COVID-19 Pandemic.
    Am J Gastroenterol. 2020 Jul 20. doi: 10.14309/ajg.0000000000000787.
    PubMed     Abstract available


  177. HAMMOUDI N, Auzolle C, Tran Minh ML, Boschetti G, et al
    Postoperative Endoscopic Recurrence on the Neoterminal Ileum But Not on the Anastomosis Is Mainly Driving Long-Term Outcomes in Crohn's Disease.
    Am J Gastroenterol. 2020;115:1084-1093.
    PubMed     Abstract available


    June 2020
  178. CALDERA F, Hayney MS, Farraye FA
    Vaccination in Patients With Inflammatory Bowel Disease.
    Am J Gastroenterol. 2020 Jun 10. doi: 10.14309/ajg.0000000000000713.
    PubMed    


  179. YANG DH, Park SJ, Kim HS
    Response to Singh et al.
    Am J Gastroenterol. 2020;115:959-960.
    PubMed    


  180. SINGH A, Narayan J, Behera MK, Mishra D, et al
    High-Definition Chromoendoscopy Was Not Superior to High-Definition White Light Endoscopy in Detecting Colitis-Associated Dysplasia, or Was It?
    Am J Gastroenterol. 2020;115:958-959.
    PubMed    


  181. ROZICH JJ, Holmer A, Singh S
    Effect of Lifestyle Factors on Outcomes in Patients With Inflammatory Bowel Diseases.
    Am J Gastroenterol. 2020;115:832-840.
    PubMed     Abstract available


    May 2020
  182. VASSEUR P, Dugelay E, Benamouzig R, Savoye G, et al
    Dietary Zinc Intake and Inflammatory Bowel Disease in the French NutriNet-Sante Cohort.
    Am J Gastroenterol. 2020 May 27. doi: 10.14309/ajg.0000000000000688.
    PubMed     Abstract available


  183. KHAN N, Patel D, Trivedi C, Kavani H, et al
    Repeated Occurrences of Basal Cell Cancer in Patients With Inflammatory Bowel Disease Treated With Immunosuppressive Medications.
    Am J Gastroenterol. 2020 May 22. doi: 10.14309/ajg.0000000000000679.
    PubMed     Abstract available


  184. DULAI PS, Battat R, Barsky M, Nguyen NH, et al
    Incorporating Fecal Calprotectin Into Clinical Practice for Patients With Moderate-to-Severely Active Ulcerative Colitis Treated With Biologics or Small-Molecule Inhibitors.
    Am J Gastroenterol. 2020 May 7. doi: 10.14309/ajg.0000000000000596.
    PubMed     Abstract available


  185. SANDS BE, Feagan BG, Sandborn WJ, Schreiber S, et al
    Mongersen (GED-0301) for Active Crohn's Disease: Results of a Phase 3 Study.
    Am J Gastroenterol. 2020;115:738-745.
    PubMed     Abstract available


  186. BEWTRA M, Lichtenstein GR
    Mongersen and SMAD-7 Inhibition, Not a Lucky 7 for Patients With IBD: When Trial Design Is as Important as Disease Therapy.
    Am J Gastroenterol. 2020;115:687-688.
    PubMed     Abstract available


  187. LEE MW, Pourmorady JS, Laine L
    Use of Fecal Occult Blood Testing as a Diagnostic Tool for Clinical Indications: A Systematic Review and Meta-Analysis.
    Am J Gastroenterol. 2020;115:662-670.
    PubMed     Abstract available


    April 2020
  188. MIRANDA E, Meza R, Kolbach M, Torres J, et al
    Sweet Syndrome in Pediatric Active Ulcerative Colitis.
    Am J Gastroenterol. 2020 Apr 27. doi: 10.14309/ajg.0000000000000645.
    PubMed    


  189. LIMDI JK
    Continuing Medical Education Questions: April 2020: Men with Inflammatory Bowel Disease: Sexual Function, Fertility, Medication Safety, and Prostate Cancer.
    Am J Gastroenterol. 2020;115:506.
    PubMed    


  190. GANZLEBEN I, Hirschmann S, Kohler J, Fuchs FS, et al
    Successful Therapy of Crohn's Disease-Associated Pulmonary Necrobiotic Nodules on Ustekinumab Therapy.
    Am J Gastroenterol. 2020;115:632-634.
    PubMed    


    March 2020
  191. SHAH A, Macdonald GA, Morrison M, Holtmann G, et al
    Targeting the Gut Microbiome as a Treatment for Primary Sclerosing Cholangitis: A Conceptional Framework.
    Am J Gastroenterol. 2020 Mar 25. doi: 10.14309/ajg.0000000000000604.
    PubMed     Abstract available


    February 2020
  192. KEDIA S, Mouli VP, Kamat N, Sankar J, et al
    Risk of Tuberculosis in Patients With Inflammatory Bowel Disease on Infliximab or Adalimumab Is Dependent on the Local Disease Burden of Tuberculosis: A Systematic Review and Meta-Analysis.
    Am J Gastroenterol. 2020 Feb 6. doi: 10.14309/ajg.0000000000000527.
    PubMed     Abstract available


  193. HAMMAMI MB, Mahadevan U
    Men With Inflammatory Bowel Disease: Sexual Function, Fertility, Medication Safety, and Prostate Cancer.
    Am J Gastroenterol. 2020 Feb 4. doi: 10.14309/ajg.0000000000000515.
    PubMed     Abstract available


    January 2020
  194. TARGOWNIK LE, Kaplan GG, Witt J, Bernstein CN, et al
    Longitudinal Trends in the Direct Costs and Health Care Utilization Ascribable to Inflammatory Bowel Disease in the Biologic Era: Results From a Canadian Population-Based Analysis.
    Am J Gastroenterol. 2020;115:128-137.
    PubMed     Abstract available


    December 2019
  195. CHATEAU T, Feakins R, Marchal-Bressenot A, Magro F, et al
    Histological Remission in Ulcerative Colitis: Under the Microscope Is the Cure.
    Am J Gastroenterol. 2019 Dec 5. doi: 10.14309/ajg.0000000000000437.
    PubMed     Abstract available


    November 2019
  196. CAZZAGON N, Lemoinne S, El Mouhadi S, Trivedi PJ, et al
    The Complementary Value of Magnetic Resonance Imaging and Vibration-Controlled Transient Elastography for Risk Stratification in Primary Sclerosing Cholangitis.
    Am J Gastroenterol. 2019 Nov 14. doi: 10.14309/ajg.0000000000000461.
    PubMed     Abstract available


  197. LEI DK, Ollech JE, Andersen M, Weisshof R, et al
    Long-Duration Oral Vancomycin to Treat Clostridioides difficile in Patients With Inflammatory Bowel Disease Is Associated With a Low Rate of Recurrence.
    Am J Gastroenterol. 2019 Nov 7. doi: 10.14309/ajg.0000000000000460.
    PubMed     Abstract available


  198. AGRAWAL S, Khanna U, Fernandez AP, Irfan M, et al
    Linear Immunoglobulin A Bullous Dermatosis Associated With Ulcerative Colitis.
    Am J Gastroenterol. 2019 Nov 6. doi: 10.14309/ajg.0000000000000449.
    PubMed    


  199. BOOTH AT, Forster E, Curran T, George V, et al
    Gastrocolic Fistula Involving the Pancreas in a Patient With Crohn's Disease.
    Am J Gastroenterol. 2019;114:1823-1824.
    PubMed    


    October 2019
  200. VISCIDO A, Latella G, Frieri G
    Topical Aminosalicylates and Histologic Healing in Ulcerative Colitis.
    Am J Gastroenterol. 2019 Oct 14. doi: 10.14309/ajg.0000000000000427.
    PubMed    


  201. YANG DH, Park SJ, Kim HS, Park YS, et al
    High-Definition Chromoendoscopy Versus High-Definition White Light Colonoscopy for Neoplasia Surveillance in Ulcerative Colitis: A Randomized Controlled Trial.
    Am J Gastroenterol. 2019;114:1642-1648.
    PubMed     Abstract available


    September 2019
  202. WALLENHORST T, Jacques J, Bouguen G, Pagenault M, et al
    Successful Closure of a Rectal Fistula of Crohn's Disease Using Endoscopic Submucosal Dissection Combined With an Over-the-Scope Clip.
    Am J Gastroenterol. 2019;114:1416.
    PubMed    


    August 2019
  203. GREUTER T, Vavricka SR, Scharl M
    Response to Al Sulais et al.
    Am J Gastroenterol. 2019;114:1346-1347.
    PubMed    


  204. AL SULAIS E, AlAmeel T
    Family History Is a Risk Factor for Developing Malignancies.
    Am J Gastroenterol. 2019;114:1346.
    PubMed    


  205. SIMSEK M, de Boer NKH
    Mesalazine and Nephrolithiasis: Leave No Stone Unturned.
    Am J Gastroenterol. 2019;114:1359-1360.
    PubMed    


  206. LU C, Holubar SD, Rieder F
    How I Approach the Management of Stricturing Crohn's Disease.
    Am J Gastroenterol. 2019;114:1181-1184.
    PubMed    


    July 2019
  207. BAR-GIL SHITRIT A, Ben Ya'acov A, Livovsky DM, Cuker T, et al
    Exposure to Vedolizumab in IBD Pregnant Women Appears of Low Risk for Mother and Neonate: A First Prospective Comparison Study.
    Am J Gastroenterol. 2019;114:1172-1175.
    PubMed     Abstract available


  208. BRAUN T, Di Segni A, BenShoshan M, Neuman S, et al
    Individualized Dynamics in the Gut Microbiota Precede Crohn's Disease Flares.
    Am J Gastroenterol. 2019;114:1142-1151.
    PubMed     Abstract available


  209. BISHNOI A, Kaushik A, Banerjee N, Nada R, et al
    Asymptomatic Macrocheilia in an Adult Woman.
    Am J Gastroenterol. 2019;114:1022.
    PubMed    


    May 2019
  210. LICHTENSTEIN GR, Loftus EV, Isaacs KL, Regueiro MD, et al
    Response to Chapman and Jones.
    Am J Gastroenterol. 2019;114:828.
    PubMed    


  211. LICHTENSTEIN GR, Loftus EV, Isaacs KL, Regueiro MD, et al
    Response to Ribaldone.
    Am J Gastroenterol. 2019;114:826-827.
    PubMed    


  212. CHAPMAN BJ, Jones GB
    Underscoring the Biochemical Overlap Between Crohn's Disease and Depression.
    Am J Gastroenterol. 2019;114:827-828.
    PubMed    


  213. RIBALDONE DG
    ACG Clinical Guideline on Crohn's Disease: A Point of View from Europe.
    Am J Gastroenterol. 2019;114:826.
    PubMed    


  214. WU J, Lubman DM, Kugathasan S, Denson LA, et al
    Serum Protein Biomarkers of Fibrosis Aid in Risk Stratification of Future Stricturing Complications in Pediatric Crohn's Disease.
    Am J Gastroenterol. 2019;114:777-785.
    PubMed     Abstract available


    April 2019
  215. JAIN A, Nguyen NH, Proudfoot JA, Martin CF, et al
    Impact of Obesity on Disease Activity and Patient-Reported Outcomes Measurement Information System (PROMIS) in Inflammatory Bowel Diseases.
    Am J Gastroenterol. 2019;114:630-639.
    PubMed     Abstract available


    March 2019
  216. SINGH S, Jairath V
    Response to Gupta and Hanauer.
    Am J Gastroenterol. 2019;114:535-536.
    PubMed    


  217. HE Y, Zhu Z, Chen Y, Chen F, et al
    Development and Validation of a Novel Diagnostic Nomogram to Differentiate Between Intestinal Tuberculosis and Crohn's Disease: A 6-year Prospective Multicenter Study.
    Am J Gastroenterol. 2019;114:490-499.
    PubMed     Abstract available


  218. GUPTA N, Hanauer SB
    Too Soon to Discard 5-ASAs?
    Am J Gastroenterol. 2019;114:534-535.
    PubMed    


    February 2019
  219. FRIEDMAN S, Norgard BM
    Response to Zhao et al.
    Am J Gastroenterol. 2019;114:358-359.
    PubMed    


  220. BERENBLUM C
    An Issue of Control: Patient Perspectives on Use of Nutritional Interventions for IBD.
    Am J Gastroenterol. 2019;114:192-193.
    PubMed    


    January 2019
  221. LICHTENSTEIN GR, Loftus EV Jr, Isaacs KL, Regueiro MD, et al
    Response to Chamberlin and Borody.
    Am J Gastroenterol. 2019;114:171-174.
    PubMed    


  222. CHAMBERLIN W, Borody T
    Comment on 2018 ACG Clinical Guideline: Antibiotics in Crohn's Disease.
    Am J Gastroenterol. 2019;114:170-171.
    PubMed    


  223. SAEZ-GONZALEZ E, Salavert M, Cerrillo E, Moret I, et al
    Secondary Haemophagocytic Syndrome and Overlapping Immune Reconstitution Syndrome: Life-Threatening Complications of Anti-TNF-alpha Treatment for Crohn's Disease.
    Am J Gastroenterol. 2019;114:177-179.
    PubMed    


  224. LIU PH, Lebwohl B, Burke KE, Ivey KL, et al
    Dietary Gluten Intake and Risk of Microscopic Colitis Among US Women without Celiac Disease: A Prospective Cohort Study.
    Am J Gastroenterol. 2019;114:127-134.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Inflammatory Bowel Diseases is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: